Bharat Biotech Awaits Approval To Roll Out Covaxin To Children Aged 2-8 Yrs

Bharat Biotech after submitting vaccine trial reports of "Covaxin" amongst beneficiaries aged between 2-8 years, said that they are awaiting the approval from the drug regulators. Upon receiving approval, Covaxin will become "one of the first vaccines in the world" to be administered to beneficiaries belonging to the said age group. After reviewing the results, the Subject Expert Committee (SEC) recommended the grant of the vaccine.